Skip to content
Study details
Enrolling now

Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder

Milky Kohno
NCT IDNCT06426303ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

100

Study length

about 4.7 years

Ages

18–60

Locations

1 site in OR

About this study

This trial is testing whether trauma affects emotion regulation, inflammation, and brain function differently between men and women with alcohol use disorder. It aims to determine how naltrexone impacts these factors and its effectiveness in reducing alcohol cravings and promoting abstinence in both sexes.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Naltrexone
PhasePhase 4
DrugNaltrexone
Routeinjection
Primary goalChange from baseline in alcohol use (number of drinking days, amount used per day)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low11%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

naltrexone

Drug routes

injection, intramuscular

Endpoints

Primary: Change from baseline in alcohol use (number of drinking days, amount used per day)

Secondary: Change from baseline in craving (include craving measures/questionnaires), Change from baseline in neuropsychological testing scores

Body systems

Psychiatry / Mental Health